Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares traded up 4.9% on Wednesday . The stock traded as high as $11.88 and last traded at $11.80. 74,849 shares traded hands during trading, a decline of 92% from the average session volume of 964,414 shares. The stock had previously closed at $11.25.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group raised their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, April 11th. TD Cowen raised Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 26th. Finally, HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $19.63.
Read Our Latest Stock Analysis on STOK
Stoke Therapeutics Price Performance
The stock has a fifty day moving average price of $9.16 and a 200-day moving average price of $6.17. The company has a market cap of $539.86 million, a PE ratio of -4.92 and a beta of 0.77.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million during the quarter, compared to analysts' expectations of $3.70 million. On average, equities analysts anticipate that Stoke Therapeutics, Inc. will post -2.28 earnings per share for the current year.
Insider Buying and Selling
In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the sale, the insider now owns 6,981 shares of the company's stock, valued at $33,508.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,632,741 shares of company stock worth $41,983,115. Corporate insiders own 12.30% of the company's stock.
Hedge Funds Weigh In On Stoke Therapeutics
Institutional investors have recently bought and sold shares of the stock. Dorsey & Whitney Trust CO LLC bought a new position in Stoke Therapeutics during the third quarter valued at about $43,000. Sherbrooke Park Advisers LLC bought a new position in Stoke Therapeutics during the third quarter valued at about $48,000. SG Americas Securities LLC bought a new position in Stoke Therapeutics during the third quarter valued at about $53,000. Corton Capital Inc. bought a new position in Stoke Therapeutics during the third quarter valued at about $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in Stoke Therapeutics during the third quarter valued at about $64,000.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Articles
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
